IMPACT Given FDA Approval to Identify Genetic Mutations

The Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) gene profiling assay is a diagnostic test devised by MSK to identify a variety of gene mutations (biomarkers) found in a variety of cancers. It was granted FDA approval last month. By identifying the mutations present in a tumor, clinicians can better treat a patient’s cancer for their exact tumor type. The IMPACT test works by comparing tumor tissue to normal tissue or cells to detect changes in the genetic makeup of the tumor that can direct treatment options.

Don’t Let Stress Get in the Way This Holiday Season

This time of year can be stressful. During the busy Holiday Season, make sure to take care of yourself. Check out the NIH’s page on Stress Relief with information for both Consumers and Health Professionals. Support for MSK Staff is available through a number of resources including Employee Wellness (internal link). Information is available at the following link for patients and their caregivers.